SIONNA THERAPEUTICS INC (SION)
Sector: Health Care
2026 Annual Meeting Analysis
SIONNA THERAPEUTICS INC · Meeting: June 17, 2026
Directors FOR
4
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Dr. Fleming joined the board in March 2024, which is within the 24-month exemption window, so he is exempt from the stock performance trigger; he has no attendance, overboarding, or independence concerns, and brings relevant healthcare and biopharma commercialization experience.
Dr. Ruddy joined the board in January 2025, well within the 24-month new-director exemption, so she is exempt from the stock performance trigger; she has no attendance, overboarding, or independence issues and brings deep drug development expertise relevant to Sionna's stage.
Sionna's 3-year stock return of +56.8% is strongly positive, and the gap versus the XBI — SPDR S&P Biotech ETF of -10.0 percentage points is far below the 65-percentage-point threshold required to trigger an against vote; Dr. Thompson has no attendance, overboarding, or independence concerns and brings relevant biotech investment and board experience.
Dr. Viney is CEO of Seismic Therapeutic and also sits on Sionna's board; the policy flags sitting CEOs who hold two or more outside public board seats, but Dr. Viney's disclosed public company board service appears limited to Sionna (her other current boards are private companies), so the overboarding trigger for sitting CEOs does not fire; she joined in January 2025 and is within the 24-month new-director exemption from the TSR trigger, and no other disqualifying factors are present.
All four Class II director nominees pass the policy screens. The stock performance trigger does not apply to Fleming, Ruddy, or Viney because they joined the board within the past 24 months and are exempt as new directors. Thompson clears the performance bar easily — Sionna's 3-year return of +56.8% is strongly positive, and the underperformance gap versus the XBI — SPDR S&P Biotech ETF of only 10 percentage points is far short of the 65-percentage-point threshold needed to trigger a against vote. No director has attendance below 75% (Resnick, who missed meetings, is not up for election this year), overboarding concerns, independence issues, or family relationships with management.
Say on Pay
✓ FORCEO
Michael Cloonan, M.B.A.
Total Comp
$6,981,217
Prior Support
N/A
Sionna is an emerging growth company and is not required to hold a Say on Pay vote; this proposal does not appear on the 2026 ballot, so no vote determination is made. The CEO's total compensation of approximately $6.98 million in 2025 is driven largely by stock option awards (about $5.95 million, or roughly 85% of total pay), which is well above the 50-60% variable pay threshold the policy favors, and the company maintains a formal clawback policy compliant with SEC and Nasdaq requirements. The annual bonus was paid at 112.5% of target, tied to disclosed corporate performance objectives, which is a reasonable outcome given Sionna's strong 1-year stock return of +223%.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
2 yrs
Audit Fees
$822,630
Non-Audit Fees
$1,895
Non-audit fees of $1,895 represent less than 1% of audit fees of $822,630, well below the 50% threshold that would raise independence concerns; Deloitte has served since at least 2024, so tenure is approximately 2 years and nowhere near the 25-year threshold; no restatements are disclosed; Deloitte is a Big 4 firm appropriate for a $1.8B market-cap company.
Overall Assessment
The 2026 Sionna Therapeutics annual meeting contains two voting items: election of four Class II directors and ratification of Deloitte & Touche LLP as auditor. All four director nominees pass the policy screens — two are new directors exempt from the TSR trigger, one clears the performance bar easily against the XBI — SPDR S&P Biotech ETF, and one (Viney) is also a new-director exempt; the auditor relationship is clean with negligible non-audit fees and a short tenure. No Say on Pay vote is on the ballot because Sionna qualifies as an emerging growth company.